Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Media

Press Releases - 2006

Newron Pharmaceuticals Reports the Start of a Pivotal Phase III Study with Safinamide in Mid-to-Late Stage Parkinson’s Disease Patients

27/11/2006
English ENG  German GER

Newron Pharmaceuticals Strengthens its Board of Directors

23/11/2006
English ENG  German GER

ION CRAFT Project co-funded by the European Commission and coordinated by Newron Pharmaceuticals is being successfully completed.

23/11/2006
English ENG   

Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide

16/10/2006
English ENG   

Newron Pharmaceuticals Reports New Data Indicating that its Novel ION Channel Blocker, Ralfinamide, May have Preemptive and Palliative Analgesic Potency Against Spontaneous Neuropathic Pain

14/09/2006
English ENG   

Newron Pharmaceuticals’ lead clinical program confirms efficacy and safety in a Phase III trial for Parkinson’s disease
- Safinamide demonstrates benefit on motor symptoms and Activities of Daily Living as well as good tolerability; improvement in cognition broadens potential scope -

19/06/2006
English ENG